Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2287]
News [5256]
Articles [128]
Editorials [4]
Conferences [157]
elearning [13]
PARP inhibitors and immunotherapy in ovarian cancer: From research to practice
PARP inhibitors and immunotherapy in ovarian cancer: From research to practice ( )
27 Jan 2020
The age of genomic profiling
Prof Cengiz Yakicier - Acıbadem University, Istanbul, Turkey
The age of genomic profiling ( Prof Cengiz Yakicier - Acıbadem University, Istanbul, Turkey )
27 Jan 2020
Identifying BRCA mutations for breast and ovarian cancer
Prof Alena Savanevich - Grodno State Medical University, Grodno, Belarus
Identifying BRCA mutations for breast and ovarian cancer ( Prof Alena Savanevich - Grodno State Medical University, Grodno, Belarus )
27 Jan 2020
Long-term toxicities in paediatric ALL
Prof Kjeld Schmiegelow - University of Copenhagen, Copenhagen, Denmark
Long-term toxicities in paediatric ALL ( Prof Kjeld Schmiegelow - University of Copenhagen, Copenhagen, Denmark )
23 Jan 2020
HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2...
Dr Rashmi Murthy - MD Anderson Cancer Center, Houston, USA
HER2CLIMB: Investigating tucatinib with capecitabine and trastuzumab in HER2-positive metastatic breast cancer ( Dr Rashmi Murthy - MD Anderson Cancer Center, Houston, USA )
23 Jan 2020
Novel therapeutic approaches in B-progenitor ALL
Dr Charles Mullighan - St. Jude's Children's Research Hospital, Memphis, USA
Novel therapeutic approaches in B-progenitor ALL ( Dr Charles Mullighan - St. Jude's Children's Research Hospital, Memphis, USA )
23 Jan 2020
Latest concepts in frontline therapy for paediatric ALL
Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA
Latest concepts in frontline therapy for paediatric ALL ( Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA )
23 Jan 2020
Is enasidenib plus azacitidine better than with azacitidine alone for AML...
Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA
Is enasidenib plus azacitidine better than with azacitidine alone for AML patients? ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )
24 Dec 2019
Lenalidomide maintenance for transplant eligible and transplant ineligible...
Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK
Lenalidomide maintenance for transplant eligible and transplant ineligible newly diagnosed myeloma patients ( Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK )
24 Dec 2019
Dasatinib vs imatinib in the treatment of paediatric ALL
Dr Shuhong Shen - National Children's Medical Center, Shanghai, China
Dasatinib vs imatinib in the treatment of paediatric ALL ( Dr Shuhong Shen - National Children's Medical Center, Shanghai, China )
24 Dec 2019
Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells...
Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern...
Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in humans ( Prof Adrian Ochsenbein - University and University Hospital of Bern, Bern, Switzerland )
19 Dec 2019
Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT...
Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA
Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo ( Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA )
19 Dec 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation